Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma [Corrigendum]
Journal of Hepatocellular Carcinoma · 2026-03 · Volume 13 · 1-1
DOI: 10.2147/jhc.s611160 ↗Kurz gefasst
Korrektur in der Zeitschrift Journal of Hepatocellular Carcinoma, 2026-03. Verfasst von Ching-Tso Chen und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Chen, C., Chuang, C., Hsu, C., & Shao, Y. (2026). Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma [Corrigendum]. Journal of Hepatocellular Carcinoma, Volume 13, 1-1. https://doi.org/10.2147/jhc.s611160
Vancouver
Chen C, Chuang C, Hsu C, Shao Y. Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma [Corrigendum]. Journal of Hepatocellular Carcinoma. 2026;Volume 13:1-1. doi:10.2147/jhc.s611160
BibTeX
@article{Chen2026,
author = {Chen, Ching-Tso and Chuang, Chien-Huai and Hsu, Chih-Hung and Shao, Yu-Yun},
title = {Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma [Corrigendum]},
journal = {Journal of Hepatocellular Carcinoma},
year = {2026},
volume = {Volume 13},
pages = {1--1},
doi = {10.2147/jhc.s611160}
}
EUVIMED